Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow IMTX by emailGet an email when IMTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMTX, unsubscribe in one click. Privacy
📣 What IMTX Says Is Next
in 2027 · “First data from the IMA402/IMA401 combination cohort are expected in 2027. 3 Mair K, et al. N Engl J Med . 2026;395:721-724 Immatics Press Release August 18, 2026 5 | 14 Corporate Development:”
Company press release, Aug 18, 2026 · SEC filing
first half of 2027 · “The Company expects to disclose topline data from the final PFS analysis in the first half of 2027, followed by a BLA submission in 2027.”
Company press release, Aug 18, 2026 · SEC filing
by year-end · “Enrollment in SUPRAME, currently ongoing in North America and Europe, remains on track to complete required randomizations by year-end to support final analysis for the primary endpoint.”
Company press release, Aug 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full IMTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.